1,2,3,4-四氢-1-氧代-2-萘乙酸甲酯 | 7430-89-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 1,2,3,4-四氢-1-氧代-2-萘乙酸甲酯
• 英文名称: methyl 2-(1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetate
• 英文别名: methyl 2-(1-oxo-3,4-dihydro-2H-naphthalen-2-yl)acetate
• CAS: 7430-89-9
• 化学式: C₁₃H₁₄O₃
• 分子量: 218.252
• InChiKey: JXGWCLZVVXSVRQ-UHFFFAOYSA-N

物化性质

• 沸点：
  332.8±11.0 °C(Predicted)
• 密度：
  1.146±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢-1-氧代-2-萘乙酸甲酯 在 palladium on activated charcoal 氢气 、 sulfur 、 zinc(II) chloride 作用下， 以 四氢呋喃 、 溶剂黄146 为溶剂， 反应 5.33h， 生成 1-(2'-methoxy-5'-methylphenyl)-2-naphthaleneacetic acid methyl ester
  参考文献：
  名称：

  Arylmagnesium bromide additions to 1-tetralone-2-acetic acid followed by catalytic hydrogenolysis: stereochemical consequences

  摘要：

  A Stork reaction route (7 --> 1b) was utilized to synthesize 1-tetralone-2-acetic acid methyl ester (1a) from 1-tetralone. Addition of a 2'-(o-methoxyphenyl) magnesium bromide to this ketone followed by palladium-catalyzed hydrogenation of the intermediate cis lactones (2, verified by X-ray crystal structure determination of 2a, Figure 1), afforded predominantly a 1,2-cis tetralin (3) accompanied by smaller yields of the corresponding 1,2-trans tetralin (4). The stereochemical consequences of this reaction sequence was unequivocally established by X-ray crystal structure elucidation of 1,2-cis methyl ester 3b (Figure 2) and 1,2-trans carboxylic acid 4a (Figure 3). Stereochemical assignments for the analogous diastereoisomeric sets 3c-f and 4c-f were obtained by high-field (400-MHz) H-1 and C-13 NMR correlations with the crystal structures. The overall reaction pathway illustrates a useful approach to 1,2-cis-alkylated tetralins and certain sterically hindered 1,2-trans-alkylated tetralins.

  DOI：

  10.1021/jo00018a030
• 作为产物：
  描述：

  1-(but-3-yn-1-yl)-2-iodobenzene 在 bis-triphenylphosphine-palladium(II) chloride 、 二异丁基氢化铝 、 三乙胺 作用下， 以 乙腈 、 苯 为溶剂， 25.0~100.0 ℃ 、4.05 MPa 条件下， 反应 21.0h， 生成 1,2,3,4-四氢-1-氧代-2-萘乙酸甲酯
  参考文献：
  名称：

  钯催化的 1-Iodo-2-烯基苯的羰基化环化

  摘要：

  ω-乙烯基取代的邻碘烯基苯 1-4 的 Pd 催化羰基化可以提供高达中等产率 (50-60%) 的 5 和 6 元 I 型环状酰基钯化产物，即 α,β-不饱和环状酮，在没有外部亲核试剂和高产率的 5 和 6 元 II 型环状酰基钯化产物，即 α-或 β-（（烷氧基羰基）甲基）取代的环酮在醇存在下，例如，甲醇。在没有此类过程可用的情况下，其他副反应，例如环状碳钯化、聚合酰基钯化以及通过酯化和其他过程捕获酰基钯可能会成为主要反应。更小，即3-或4-元，或7-元或更大的环酮似乎不能通过反应获得。在大多数情况下，外模式循环酰基钯化仅发生。然而，3 的环状酰基钯化仅通过内模式环化进行，得到 5 元酮。替代一种或多种氢...

  DOI：

  10.1021/ja9533196

文献信息

• Multiple Absolute Stereocontrol in Cascade Lactone Formation via Dynamic Kinetic Resolution Driven by the Asymmetric Transfer Hydrogenation of Keto Acids with Oxo-Tethered Ruthenium Catalysts
  作者：Taichiro Touge、Kazuhiko Sakaguchi、Nao Tamaki、Hideki Nara、Tohru Yokozawa、Kazuhiko Matsumura、Yoshihito Kayaki

  DOI：10.1021/jacs.9b07297

  日期：2019.10.16

  straightforward asymmetric construction of chiral fused γ- and δ-lactones containing multiple contiguous stereocenters was successfully developed by either (1) the dynamic kinetic resolution-asymmetric transfer hydrogenation (DKR-ATH) reaction using oxo-tethered Ru(II) complexes followed by syn-selective lactonization or (2) the tandem DKR-ATH/lactonization in combination with asymmetric hydrogenation

  包含多个连续立体中心的手性稠合 γ- 和 δ-内酯的直接不对称结构通过以下任一方法成功开发：（1）使用氧系连接的 Ru（II）配合物的动态动力学拆分 - 不对称转移氢化（DKR-ATH）反应，然后是顺选择性内酯化或 (2) 串联 DKR-ATH/内酯化与 Ru-手性二膦配合物催化的不对称氢化相结合。该权宜之计适用于天然葡萄酒内酯和生物活性苯并稠合内酯的对映选择性合成，具有前所未有的非对映选择性和对映选择性。
• DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
  申请人：——

  公开号：US20030082623A1

  公开（公告）日：2003-05-01

  This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention provides a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of an MCH1 antagonist effective to decrease the body mass of the subject and/or decrease the consumption of food by the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's depression and/or anxiety.

  这项发明提供了编码人类MCH1受体的孤立核酸，纯化的人类MCH1受体，包括编码人类MCH1受体的孤立核酸的载体，包含这种载体的细胞，针对人类MCH1受体的抗体，用于检测编码人类MCH1受体的核酸探针，互补于编码人类MCH1受体独特序列的反义寡核苷酸，表达编码正常或突变人类MCH1受体的转基因非人类动物，孤立人类MCH1受体的分离方法，治疗与人类MCH1受体活性相关的异常的方法，以及确定化合物与哺乳动物MCH1受体结合的方法。这项发明提供了一种修改受试者摄食行为的方法，包括向受试者投与足以减少受试者体重和/或减少受试者食物摄入量的MCH1拮抗剂的量。这项发明还提供了一种治疗患有抑郁和/或焦虑的受试者的方法，包括向受试者投与足以治疗受试者抑郁和/或焦虑的MCH1拮抗剂的量。
• Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
  申请人：——

  公开号：US20030069261A1

  公开（公告）日：2003-04-10

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

  这项发明涉及选择性拮抗黑素浓集激素-1（MCH1）受体的化合物。该发明提供了一种包括所述化合物的治疗有效量和药学可接受载体的药物组合物。该发明提供了一种通过结合本发明化合物的治疗有效量和药学可接受载体制备的药物组合物。该发明还提供了一种制备药物组合物的方法，包括结合本发明化合物的治疗有效量和药学可接受载体。该发明还提供了一种修改受试者进食行为的方法，包括向受试者投与本发明化合物的有效量以减少受试者的食物摄入量。该发明还提供了一种治疗受试者进食障碍的方法，包括向受试者投与本发明化合物的有效量以减少受试者的食物摄入量。在该发明实施方式中，进食障碍可以是暴食症、暴食症神经质或肥胖症。
• Dieckmann cyclisation of some β,γ-unsaturated dimethyl esters—II
  作者：A.K. Sarkar、A. Chatterjee

  DOI：10.1016/0040-4020(76)80023-3

  日期：1976.1

  Further studies of Dieckmann cyclisation are described based on unsaturated heptanedioic acid diesters 1 and 9.

  基于不饱和庚二酸二酯1和9描述了Dieckmann环化的进一步研究。
• [EN] SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES SELECTIFS DES RECEPTEURS (MCH1) D'HORMONE-1 DE CONCENTRATION DE LA MELANINE ET UTILISATION DE CEUX-CI
  申请人：SYNAPTIC PHARMARCEUTICAL CORP

  公开号：WO2002006245A1

  公开（公告）日：2002-01-24

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供一种制药组合物，包括本发明的化合物的治疗有效量和药学上可接受的载体。本发明提供了一种制药组合物，其由本发明的化合物的治疗有效量和药学上可接受的载体组合而成。本发明还提供一种制备制药组合物的方法，包括将本发明的化合物的治疗有效量和药学上可接受的载体组合。本发明还提供了一种修改受试者进食行为的方法，包括向受试者施用本发明的化合物的有效量，以减少受试者的食物摄入量。本发明还提供了一种治疗受试者进食障碍的方法，包括向受试者施用本发明的化合物的有效量，以减少受试者的食物摄入量。在本发明的实施方式中，进食障碍是贪食症、神经性贪食症或肥胖症。